796 related articles for article (PubMed ID: 24144967)
21. Pegvisomant in combination with long-acting somatostatin analogues in acromegaly: the role of the GH receptor deletion of exon 3.
Franck SE; van der Lely AJ; Delhanty PJ; Jørgensen JO; Neggers SJ
Eur J Endocrinol; 2015 Nov; 173(5):553-61. PubMed ID: 26243033
[TBL] [Abstract][Full Text] [Related]
22. Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study.
Bronstein MD; Fleseriu M; Neggers S; Colao A; Sheppard M; Gu F; Shen CC; Gadelha M; Farrall AJ; Hermosillo Reséndiz K; Ruffin M; Chen Y; Freda P;
BMC Endocr Disord; 2016 Apr; 16():16. PubMed ID: 27039081
[TBL] [Abstract][Full Text] [Related]
23. Control of disease activity and tumor size after introduction of pegvisomant in a lanreotide-resistant acromegalic patient.
Fendri S; Karaca P; Tiev E; Buchfelder M; Lalau JD
Ann Endocrinol (Paris); 2013 Feb; 74(1):49-52. PubMed ID: 23337021
[TBL] [Abstract][Full Text] [Related]
24. Lanreotide Autogel 120 mg at extended dosing intervals in patients with acromegaly biochemically controlled with octreotide LAR: the LEAD study.
Neggers SJ; Pronin V; Balcere I; Lee MK; Rozhinskaya L; Bronstein MD; Gadelha MR; Maisonobe P; Sert C; van der Lely AJ;
Eur J Endocrinol; 2015 Sep; 173(3):313-23. PubMed ID: 26047625
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of combined octreotide and cabergoline treatment in patients with acromegaly: a retrospective clinical study and review of the literature.
Suda K; Inoshita N; Iguchi G; Fukuoka H; Takahashi M; Nishizawa H; Yamamoto M; Yamada S; Takahashi Y
Endocr J; 2013; 60(4):507-15. PubMed ID: 23291436
[TBL] [Abstract][Full Text] [Related]
26. Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study.
Sheppard M; Bronstein MD; Freda P; Serri O; De Marinis L; Naves L; Rozhinskaya L; Hermosillo Reséndiz K; Ruffin M; Chen Y; Colao A
Pituitary; 2015 Jun; 18(3):385-94. PubMed ID: 25103549
[TBL] [Abstract][Full Text] [Related]
27. Medical therapy for acromegaly.
Newman CB
Endocrinol Metab Clin North Am; 1999 Mar; 28(1):171-90. PubMed ID: 10207690
[TBL] [Abstract][Full Text] [Related]
28. Use of lanreotide in combination with cabergoline or pegvisomant in patients with acromegaly in the clinical practice: The ACROCOMB study.
Puig-Domingo M; Soto A; Venegas E; Vilchez R; Blanco C; Cordido F; Lucas T; Marazuela M; Casany R; Cuatrecasas G; Fajardo C; Gálvez MÁ; Maraver S; Martín T; Romero E; Paja M; Picó A; Bernabeu I; Resmini E;
Endocrinol Nutr; 2016 Oct; 63(8):397-408. PubMed ID: 27448708
[TBL] [Abstract][Full Text] [Related]
29. Long-term safety and treatment outcomes of pegvisomant in Japanese patients with acromegaly: results from the post-marketing surveillance.
Yamaguchi H; Shimatsu A; Okayama A; Sato T
Endocr J; 2020 Feb; 67(2):201-210. PubMed ID: 31723069
[TBL] [Abstract][Full Text] [Related]
30. Long-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa.
Maiza JC; Vezzosi D; Matta M; Donadille F; Loubes-Lacroix F; Cournot M; Bennet A; Caron P
Clin Endocrinol (Oxf); 2007 Aug; 67(2):282-9. PubMed ID: 17524029
[TBL] [Abstract][Full Text] [Related]
31. Current therapy and drug pipeline for the treatment of patients with acromegaly.
Kumar SS; Ayuk J; Murray RD
Adv Ther; 2009 Apr; 26(4):383-403. PubMed ID: 19444656
[TBL] [Abstract][Full Text] [Related]
32. [Therapeutic management of acromegaly].
Metzner C; Hadziselimovic S; Grafe I; Nawroth P; Kasperk C
Med Klin (Munich); 2006 Jan; 101(1):15-23. PubMed ID: 16418810
[TBL] [Abstract][Full Text] [Related]
33. Coadministration of lanreotide Autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone.
van der Lely AJ; Bernabeu I; Cap J; Caron P; Colao A; Marek J; Neggers S; Birman P
Eur J Endocrinol; 2011 Mar; 164(3):325-33. PubMed ID: 21148630
[TBL] [Abstract][Full Text] [Related]
34. Beneficial effect of dose escalation and surgical debulking in patients with acromegaly treated with somatostatin analogs in a Romanian tertiary care center.
Gheorghiu ML; Găloiu S; Vintilă M; Purice M; Hortopan D; Dumitraşcu A; Coculescu M; Poiană C
Hormones (Athens); 2016 Apr; 15(2):224-234. PubMed ID: 27376425
[TBL] [Abstract][Full Text] [Related]
35. Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly.
Colao A; Auriemma RS; Pivonello R; Kasuki L; Gadelha MR
Pituitary; 2016 Jun; 19(3):235-47. PubMed ID: 26519143
[TBL] [Abstract][Full Text] [Related]
36. Growth hormone receptor antagonists.
van der Lely AJ; Kopchick JJ
Neuroendocrinology; 2006; 83(3-4):264-8. PubMed ID: 17047392
[TBL] [Abstract][Full Text] [Related]
37. New medical therapies of acromegaly.
Maffezzoni F; Frara S; Doga M; Mazziotti G; Giustina A
Growth Horm IGF Res; 2016; 30-31():58-63. PubMed ID: 27745780
[TBL] [Abstract][Full Text] [Related]
38. The place of pegvisomant in the acromegaly treatment algorithm.
Paisley AN; Trainer PJ; Drake WM
Growth Horm IGF Res; 2004 Jun; 14 Suppl A():S101-6. PubMed ID: 15135788
[TBL] [Abstract][Full Text] [Related]
39. Body mass index and insulin-like growth factor 1 as risk factors for discordant growth hormone and insulin-like growth factor 1 levels following pituitary surgery in acromegaly.
Zhang S; Li Y; Guo X; Gao L; Lian W; Yao Y; Feng M; Bao X; Wang R; Xing B
J Formos Med Assoc; 2018 Jan; 117(1):34-41. PubMed ID: 28341329
[TBL] [Abstract][Full Text] [Related]
40. Effectiveness of adding dopamine agonist therapy to long-acting somatostatin analogues in the management of acromegaly.
Selvarajah D; Webster J; Ross R; Newell-Price J
Eur J Endocrinol; 2005 Apr; 152(4):569-74. PubMed ID: 15817912
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
